To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma...
Date First Received: January 3, 2003
Last Updated: August 4, 2008
Verified by: Alcon Research, August 2008
Clinical Trial Phase: Phase 3 | Start Date: January 2000
Overall Status: Completed
Brief Summary
Official Title: “A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.”
Condition Keyword(s):
Intervention(s):
To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Study Primary Completion Date: June 2003
Intervention(s) in this Clinical Trial
- Drug: Travoprost (0.004%)
- Drug: Latanoprost (0.005%)
Criteria for Participation in this Clinical Trial
- Adult patients of any race and either sex with chronic angle-closure glaucoma.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Alcon Research
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00051181
Study ID Number: C-01-38
ClinicalTrials.gov Identifier: NCT00051181
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
